Pioglitazone hydrochloride exhibits antiinflammatory and antiarteriosclerotic effects. It is used to prevent L-NAME-induced coronary inflammation and arteriosclerosis and to suppress increased TNF-α mRNA produced by aspirin-induced gastric mucosal injury. Pioglitazone Hydrochloride is an activator of PPAR γ. It is a PPARγ agonist and thiazolidinedione (TZD) anti-diabetic. Pioglitazone is a selective agonist of the nuclear receptor peroxisome proliferator-activated receptor γ (PPAR-γ) and to a lesser extent PPAR-α.
S Kersten; B Desvergne; W Wahli. Roles of PPARs in health and disease. Nature.2000, 405 (6785), 421-424.
Klemens Budde; Hans-Hellmut Neumayer; Lutz Fritsche; Wladyslaw Sulowicz; Tomasz Stompôr; David Eckland. The pharmacokinetics of pioglitazone in patients with impaired renal function. British Journal of Clinical Pharmacology.2003, 55 (4), 368-374.
Hazard Statements: H319
Causes serious eye irritation.
Precautionary Statements: P280i-P264-P305+P351+P338-P337+P313
Wear eye/face protection. Wash thoroughly after handling. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.